BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 38632314)

  • 1. KRAS G12 mutations as adverse prognostic factors in KMT2A-rearranged acute myeloid leukemia.
    Iyoda S; Yoshida K; Shoji K; Ito N; Tanaka M; Nannya Y; Yamato G; Tsujimoto S; Shiba N; Hayashi Y; Shiozawa Y; Shiraishi Y; Chiba K; Okada A; Tanaka H; Miyano S; Koga Y; Goto H; Moritake H; Terui K; Ito E; Kiyokawa N; Tomizawa D; Taga T; Tawa A; Takita J; Nishikori M; Adachi S; Ogawa S; Matsuo H
    Leukemia; 2024 Apr; ():. PubMed ID: 38632314
    [No Abstract]   [Full Text] [Related]  

  • 2. Mutational landscape and clinical outcome of pediatric acute myeloid leukemia with 11q23/KMT2A rearrangements.
    Yuen KY; Liu Y; Zhou YZ; Wang Y; Zhou DH; Fang JP; Xu LH
    Cancer Med; 2023 Jan; 12(2):1418-1430. PubMed ID: 35833755
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytogenetic and molecular genetic characterization of KMT2A-PTD positive acute myeloid leukemia in comparison to KMT2A-Rearranged acute myeloid leukemia.
    Vetro C; Haferlach T; Meggendorfer M; Stengel A; Jeromin S; Kern W; Haferlach C
    Cancer Genet; 2020 Jan; 240():15-22. PubMed ID: 31698332
    [TBL] [Abstract][Full Text] [Related]  

  • 4. De novo activating mutations drive clonal evolution and enhance clonal fitness in KMT2A-rearranged leukemia.
    Hyrenius-Wittsten A; Pilheden M; Sturesson H; Hansson J; Walsh MP; Song G; Kazi JU; Liu J; Ramakrishan R; Garcia-Ruiz C; Nance S; Gupta P; Zhang J; Rönnstrand L; Hultquist A; Downing JR; Lindkvist-Petersson K; Paulsson K; Järås M; Gruber TA; Ma J; Hagström-Andersson AK
    Nat Commun; 2018 May; 9(1):1770. PubMed ID: 29720585
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutational landscape and clinical outcome of patients with de novo acute myeloid leukemia and rearrangements involving 11q23/
    Bill M; Mrózek K; Kohlschmidt J; Eisfeld AK; Walker CJ; Nicolet D; Papaioannou D; Blachly JS; Orwick S; Carroll AJ; Kolitz JE; Powell BL; Stone RM; de la Chapelle A; Byrd JC; Bloomfield CD
    Proc Natl Acad Sci U S A; 2020 Oct; 117(42):26340-26346. PubMed ID: 33020282
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunotherapy- (Blinatumomab-) Related Lineage Switch of
    He RR; Nayer Z; Hogan M; Cuevo RS; Woodward K; Heyer D; Curtis CA; Peterson JF
    Case Rep Hematol; 2019; 2019():7394619. PubMed ID: 31885955
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Combination of Curaxin CBL0137 and Histone Deacetylase Inhibitor Panobinostat Delays KMT2A-Rearranged Leukemia Progression.
    Xiao L; Karsa M; Ronca E; Bongers A; Kosciolek A; El-Ayoubi A; Revalde JL; Seneviratne JA; Cheung BB; Cheung LC; Kotecha RS; Newbold A; Bjelosevic S; Arndt GM; Lock RB; Johnstone RW; Gudkov AV; Gurova KV; Haber M; Norris MD; Henderson MJ; Somers K
    Front Oncol; 2022; 12():863329. PubMed ID: 35677155
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Case report: Genomic analysis of a therapy-related chronic myelomonocytic leukemia with
    Suzuki T; Yokomori R; Sanda T; Kikuchi T; Marumo Y; Kinoshita S; Narita T; Masaki A; Ito A; Ri M; Kusumoto S; Komatsu H; Inagaki H; Iida S
    Front Oncol; 2023; 13():1116418. PubMed ID: 36874114
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Single-cell transcriptomics reveals a distinct developmental state of KMT2A-rearranged infant B-cell acute lymphoblastic leukemia.
    Khabirova E; Jardine L; Coorens THH; Webb S; Treger TD; Engelbert J; Porter T; Prigmore E; Collord G; Piapi A; Teichmann SA; Inglott S; Williams O; Heidenreich O; Young MD; Straathof K; Bomken S; Bartram J; Haniffa M; Behjati S
    Nat Med; 2022 Apr; 28(4):743-751. PubMed ID: 35288693
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hematopoietic stem cell transplantation for pediatric acute myeloid leukemia patients with KMT2A rearrangement; A nationwide retrospective analysis in Japan.
    Miyamura T; Kudo K; Tabuchi K; Ishida H; Tomizawa D; Adachi S; Goto H; Yoshida N; Inoue M; Koh K; Sasahara Y; Fujita N; Kakuda H; Noguchi M; Hiwatari M; Hashii Y; Kato K; Atsuta Y; Okamoto Y
    Leuk Res; 2019 Dec; 87():106263. PubMed ID: 31707119
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PAX5 alterations in an infant case of KMT2A-rearranged leukemia with lineage switch.
    Nakajima K; Kubota H; Kato I; Isobe K; Ueno H; Kozuki K; Tanaka K; Kawabata N; Mikami T; Tamefusa K; Nishiuchi R; Saida S; Umeda K; Hiramatsu H; Adachi S; Takita J
    Cancer Sci; 2022 Jul; 113(7):2472-2476. PubMed ID: 35467057
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of KMT2A Rearrangement and CSPG4 Expression in Pediatric Acute Myeloid Leukemia.
    Hoffmeister LM; Orhan E; Walter C; Niktoreh N; Hanenberg H; von Neuhoff N; Reinhardt D; Schneider M
    Cancers (Basel); 2021 Sep; 13(19):. PubMed ID: 34638301
    [No Abstract]   [Full Text] [Related]  

  • 13. CRISPR-Cas9 Library Screening Identifies Novel Molecular Vulnerabilities in
    Schneider P; Wander P; Arentsen-Peters STCJM; Vrenken KS; Rockx-Brouwer D; Adriaanse FRS; Hoeve V; Paassen I; Drost J; Pieters R; Stam RW
    Int J Mol Sci; 2023 Aug; 24(17):. PubMed ID: 37686014
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Impact of PI3-kinase/RAS Pathway Cooperating Mutations in the Evolution of
    Esposito MT
    Hemasphere; 2019 Jun; 3(3):e195. PubMed ID: 31723831
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fusion partner-specific mutation profiles and KRAS mutations as adverse prognostic factors in MLL-rearranged AML.
    Matsuo H; Yoshida K; Nakatani K; Harata Y; Higashitani M; Ito Y; Kamikubo Y; Shiozawa Y; Shiraishi Y; Chiba K; Tanaka H; Okada A; Nannya Y; Takeda J; Ueno H; Kiyokawa N; Tomizawa D; Taga T; Tawa A; Miyano S; Meggendorfer M; Haferlach C; Ogawa S; Adachi S
    Blood Adv; 2020 Oct; 4(19):4623-4631. PubMed ID: 32991719
    [TBL] [Abstract][Full Text] [Related]  

  • 16. KMT2A-rearranged infantile acute myeloid leukemia masquerading as juvenile myelomonocytic leukemia.
    Kanayama T; Imamura T; Kawabe Y; Osone S; Tahara J; Iwasaki F; Miyagawa N; Goto H; Imashuku S; Hosoi H
    Int J Hematol; 2018 Dec; 108(6):665-669. PubMed ID: 30143999
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhancer-activated RET confers protection against oxidative stress to KMT2A-rearranged acute myeloid leukemia.
    Frett B; Stephens KE; Koss B; Melnyk S; Farrar J; Saha D; Roy Choudhury S
    Cancer Sci; 2024 Mar; 115(3):963-973. PubMed ID: 38226414
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Duplex Sequencing Uncovers Recurrent Low-frequency Cancer-associated Mutations in Infant and Childhood
    Pilheden M; Ahlgren L; Hyrenius-Wittsten A; Gonzalez-Pena V; Sturesson H; Hansen Marquart HV; Lausen B; Castor A; Pronk CJ; Barbany G; Pokrovskaja Tamm K; Fogelstrand L; Lohi O; Norén-Nyström U; Asklin J; Chen Y; Song G; Walsh M; Ma J; Zhang J; Saal LH; Gawad C; Hagström-Andersson AK
    Hemasphere; 2022 Oct; 6(10):e785. PubMed ID: 36204688
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Whole transcriptome sequencing reveals a KMT2A-USP2 fusion in infant acute myeloid leukemia.
    Ikeda J; Shiba N; Tsujimoto SI; Yoshida M; Nakabayashi K; Ogata-Kawata H; Okamura K; Takeuchi M; Osumi T; Tomizawa D; Hata K; Kiyokawa N; Ito S; Kato M
    Genes Chromosomes Cancer; 2019 Sep; 58(9):669-672. PubMed ID: 30869817
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combinatorial efficacy of entospletinib and chemotherapy in patient-derived xenograft models of infant acute lymphoblastic leukemia.
    Loftus JP; Yahiaoui A; Brown PA; Niswander LM; Bagashev A; Wang M; Schauf A; Tannheimer S; Tasian SK
    Haematologica; 2021 Apr; 106(4):1067-1078. PubMed ID: 32414848
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.